GLP-1 Weight Loss in Grand Rapids: Costs and Coverage After Michigan Medicaid's January Cut
Grand Rapids' adult obesity rate, the January 2026 Michigan Medicaid reduction administered locally by Priority Health, published clinic prices, and the fresh LI-Grand Rapids shortage designation.
36.4% of Grand Rapids adults have obesity, per the CDC's PLACES place-level estimates from the 2023 BRFSS, crude prevalence 1. Michigan's adult rate is 35.4% 3 and Kent County's is 34.8% 2, so the city runs ahead of both its county and its state, though not by much.
The tight gradient is not the story on this page. What changed for Grand Rapids households this year is coverage, and it changed on January 1.
Grand Rapids carries two active HRSA shortage designations for its low-income population (HPSA name “LI-Grand Rapids,” designation population 74,654): a Primary Care HPSA, status Designated, score 12, designated Feb 11, 2026, with a computed shortage of 5.55 primary-care FTEs against 19.33 present; and a Mental Health HPSA, score 10, designated Mar 12, 2026 (shortage 1.74 FTEs). No dental HPSA covers the city centroid. Roughly 75,000 low-income Grand Rapids residents sit inside a freshly designated federal primary-care shortage area even though the city anchors West Michigan’s “Medical Mile.” Source: HRSA Health Professional Shortage Area data, queried via HRSA’s ArcGIS service (gisportal.hrsa.gov), Aug 27, 2026.13
Specialist access
Specialist supply is unusually strong for a tier-2 metro — the barrier is coverage and cash price, not geography. Corewell Health (Michigan’s largest health system, headquartered in Grand Rapids) runs a comprehensive weight-management service line with obesity-medicine physicians listed for Grand Rapids on its ProviderMatch directory, a Bariatric Medicine clinic at 4069 Lake Dr SE, and an accredited Comprehensive Center for bariatric surgery at Blodgett Hospital. Independent comprehensive group Grand Health Partners (2060 East Paris Ave SE) offers surgical plus non-surgical medication programs but directs patients to insurance for GLP-1 costs with no published cash pricing. Checked Aug 27, 2026.1718
Medicaid coverage note
Effective for dates of service on or after Jan 1, 2026 — mandated by Public Act 22 of 2025, the FY2026 state budget — Michigan Medicaid reduced GLP-1 coverage when used solely for obesity (Wegovy, Zepbound, Saxenda and generic liraglutide). MDHHS provider letter L 25-73 (Dec 8, 2025) sets the new prior-authorization bar: the patient must be “classified as morbidly obese,” must document failure of all other clinically appropriate weight-loss interventions (including trial and failure of PDL-preferred anti-obesity agents), and coverage may be considered only to avert higher-cost bariatric surgery. The letter itself names no BMI number; the implementing Medicaid plans’ published 2026 PA criteria operationalize “morbidly obese” as baseline BMI 40 or higher (e.g., Aetna Better Health MI HIDE criteria, Dec 2025; U-M IHPI reads the policy the same way) — leaving the BMI 30–39.9 cohort with no obesity-indication path once existing authorizations lapse (pre-2026 approvals honored for up to six remaining months). Type 2 diabetes coverage (Ozempic, Mounjaro) continues, and Zepbound for obstructive sleep apnea and Wegovy for cardiovascular risk remain coverable with prior auth. Grand Rapids-headquartered Priority Health published its Medicaid implementation Dec 15, 2025. Bridge Michigan reports the cut saves roughly $240M, with ~90,324 Medicaid GLP-1 users in FY2024, about 40% for weight loss (journalistic figures, not independently reproduced from state documents). Status as of Aug 27, 2026.7
What changed on January 1
Effective for dates of service on or after Jan 1, 2026, mandated by Public Act 22 of 2025, the FY2026 state budget, Michigan Medicaid reduced GLP-1 coverage when the drugs are used solely for obesity: Wegovy, Zepbound, and Saxenda or generic liraglutide 7. MDHHS provider letter L 25-73 sets the bar: the patient must be "classified as morbidly obese," must document failure of all other clinically appropriate weight-loss interventions including trial and failure of PDL-preferred anti-obesity agents, and coverage may be considered only to avert higher-cost bariatric surgery 7.
The letter itself never names a BMI number. The "BMI 40 or higher" figure comes from the implementing Medicaid plans' published 2026 prior-authorization criteria 8 and from the University of Michigan IHPI's reading of the change 12, and should be attributed there rather than to the state letter.
The local hinge is that Priority Health, headquartered in Grand Rapids, administers the change for its own Medicaid members, per its provider bulletin of Dec 15, 2025 9; Meridian issued the parallel notice 10. Authorizations granted before 2026 were honored for up to six remaining months, so the last of them are lapsing right now 9. Type 2 diabetes coverage continues for Ozempic and Mounjaro, and Zepbound for sleep apnea and Wegovy for cardiovascular risk stay coverable with prior authorization 7. Bridge Michigan reported the state expected roughly $240 million in savings, a journalism figure rather than a state document 11. The reader this page serves is the one with a BMI of 30 to 39.9 whose authorization has just lapsed.
What GLP-1 care costs in Grand Rapids today
Vivid IV Health on Commerce Ave SW publishes compounded semaglutide "Starting at $199/month" and compounded tirzepatide "Starting at $299/month" 14. "Starting at" means dose-escalation pricing: the number quoted is the entry dose, not the maintenance one. Advanced Plastic Surgery's own semaglutide page states that "you can pay about $400 to $500 per month," a typical-cost statement rather than a menu price, with the exact figure depending on medication, dosage, and insurance 15.
Everyone else is opaque. Skin Envy advertises "40% Reduced Pricing on GLP-1 Plans" while publishing zero dollar figures 16, and Grand Health Partners 18, Grand Pearl Spa, RegenCen East Grand Rapids, The DRIPBaR Grand Rapids, and Urban You, which promises "flat-rate pricing" without stating the rate, publish no prices either. In this market a posted price is itself the differentiator.
Astra's national price, once: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, $816 and $1,416 a year. Same price in every city, same price at every dose. There is no Grand Rapids rate or discount.
Strong on specialists, short on access
Grand Rapids anchors West Michigan's Medical Mile, and the specialist supply reflects it. Corewell Health, Michigan's largest health system and headquartered here, runs a weight-management service line with obesity-medicine physicians listed for Grand Rapids, a Bariatric Medicine clinic at 4069 Lake Dr SE, and an accredited comprehensive center for bariatric surgery at Blodgett Hospital 17. Grand Health Partners on East Paris Ave SE adds an independent surgical and non-surgical program, though it directs patients to insurance for GLP-1 costs with no published cash pricing 18.
The barrier is therefore coverage and cash price, not geography, and it arrived at the moment Medicaid narrowed. Meanwhile about 75,000 low-income residents sit inside the LI-Grand Rapids primary-care HPSA, score 12, designated Feb 11, 2026, a fresh federal designation, with a computed shortage of 5.55 primary-care FTEs; a matching mental health HPSA, score 10, followed on Mar 12, 2026 13.
Telehealth's honest role in a city with this much clinical depth is narrow and specific: a posted flat price and a path that does not depend on the coverage the reader just lost. State-level rules are on the Michigan GLP-1 hub.
Astra treats patients in Michigan through state-licensed physicians.
Local options
Vivid IV Health (38 Commerce Ave SW, Suite 102, Grand Rapids) — Published program pricing: compounded semaglutide “Starting at $199/month”; compounded tirzepatide “Starting at $299/month” (flagged “Most Popular”) — monthly structure, with lifestyle support and lab testing available via insurance or discounted self-pay. https://vividivhealth.com/weight-management-program/(checked 2026-08-27)
Advanced Plastic Surgery / Dr. Ewa Timek (Grand Rapids) — Practice’s own semaglutide page publishes a typical-cost statement: “you can pay about $400 to $500 per month,” with exact cost depending on medication, dosage, and insurance — a per-month typical-cost statement, not a fixed menu price. https://drtimek.com/non-surgical-grand-rapids/semaglutide/(checked 2026-08-27)
Skin Envy Non-Surgical Weight Loss Center (3425 Lake Eastbrook Blvd, Grand Rapids) — opacity finding — Advertises “40% Reduced Pricing on GLP-1 Plans” on its homepage but publishes zero dollar figures — teaser-discount-without-price. Same opacity found at Grand Health Partners, Grand Pearl Spa (220 Lyon St NW), RegenCen East Grand Rapids, The DRIPBaR Grand Rapids, and Urban You (which promises “flat-rate pricing” without stating the rate). All checked Aug 27, 2026. https://www.removefat.com/(checked 2026-08-27)
Frequently asked questions
Did Michigan Medicaid stop covering Wegovy and Zepbound for weight loss in 2026?
Largely, yes. Effective Jan 1, 2026, Michigan Medicaid covers GLP-1s prescribed solely for obesity (Wegovy, Zepbound, Saxenda/liraglutide) only under a far stricter prior authorization set by MDHHS letter L 25-73: the patient must be “classified as morbidly obese” — operationalized by the implementing Medicaid plans as baseline BMI 40 or higher — with documented failure of all other clinically appropriate weight-loss interventions, and only to avert bariatric surgery. Coverage for type 2 diabetes (Ozempic, Mounjaro), Zepbound for sleep apnea, and Wegovy for cardiovascular risk continues with prior auth. Pre-2026 approvals were honored for up to six remaining months, so the last of them are lapsing about now.
What BMI do I need for Michigan Medicaid to cover a GLP-1 in Grand Rapids now?
The state’s letter never names a number — it requires that you be “classified as morbidly obese,” have documented failure of all other clinically appropriate weight-loss interventions (including preferred anti-obesity agents on the state drug list), and that the drug be used only to avert bariatric surgery. The Medicaid health plans implementing the policy publish the number: baseline BMI 40 or higher. If your BMI is between 30 and 39.9, Michigan Medicaid no longer offers an obesity-indication path once an existing authorization lapses.
How much does semaglutide cost in Grand Rapids without insurance?
Published Grand Rapids prices, checked Aug 27, 2026: Vivid IV Health posts compounded semaglutide starting at $199/month and compounded tirzepatide starting at $299/month; Advanced Plastic Surgery (Dr. Timek) publishes a typical cost of about $400–$500/month depending on medication and dose. Most other local weight-loss providers — including Corewell Health’s programs, Grand Health Partners, and Skin Envy — publish no dollar figures at all. Astra’s telehealth price in Grand Rapids is the same as everywhere: $68/month for compounded semaglutide and $118/month for compounded tirzepatide on a 12-month plan, at every dose.
My Priority Health Medicaid plan denied my GLP-1 renewal — what are my options in Grand Rapids?
Priority Health administers the state’s Jan 1, 2026 Medicaid change (its implementation bulletin published Dec 15, 2025), so a denial likely reflects the new state criteria rather than a plan-specific decision. Your options: appeal with documentation if you believe you meet the morbid-obesity criteria; ask your provider whether a still-covered indication applies (type 2 diabetes, Zepbound for obstructive sleep apnea, Wegovy for cardiovascular risk — all with prior auth); or move to cash pay, where published Grand Rapids programs run $199–$500/month and Astra’s national 12-month plan price is $68/month for semaglutide or $118/month for tirzepatide.
Is Astra cheaper in Grand Rapids than a local clinic?
Yes, against every published local price — and not because of any Grand Rapids discount. Astra charges one national price: $68/month for compounded semaglutide and $118/month for compounded tirzepatide on 12-month plans ($816 and $1,416 a year), the same at every dose. The lowest published clinic price we found in Grand Rapids is $199/month (Vivid IV Health, compounded semaglutide, checked Aug 27, 2026) — about $2,388 a year — and one practice’s published typical cost is $400–$500/month. Several other local providers publish no prices at all.